Protara Therapeutics Announces Dosing of First Patient In Phase 1b/2 ADVANCED-2 Trial Of TARA-002 In NMIBC Patients With High Grade Carcinoma In Situ
Portfolio Pulse from Benzinga Newsdesk
Protara Therapeutics has announced the dosing of the first patient in its Phase 1b/2 ADVANCED-2 trial of TARA-002 in patients with high grade carcinoma in situ. This marks a significant step in the development of the drug.
September 20, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Protara Therapeutics has started dosing in its Phase 1b/2 trial of TARA-002. This could potentially lead to positive outcomes for the company if the trial results are successful.
The initiation of dosing in a clinical trial is a significant step in the development of a drug. If the trial results are positive, it could potentially lead to the approval of the drug, which would be a major boost for the company. Therefore, this news is highly relevant and important for Protara Therapeutics.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100